Basit öğe kaydını göster

dc.contributor.authorRakıcı, Halil
dc.contributor.authorAkdoğan, Remzi Adnan
dc.contributor.authorBedir, Recep
dc.contributor.authorÇiçek, Ayşegül Çopur
dc.contributor.authorYılmaz, Arif
dc.date.accessioned2020-12-19T20:03:03Z
dc.date.available2020-12-19T20:03:03Z
dc.date.issued2014
dc.identifier.citationRakici, H., Akdogan, R.A., Bedir, R., Cicek, A.C., Yilmaz, A. (2014). Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates. Journal of Digestive Diseases, 15(9), 508-513. https://doi.org/10.1111/1751-2980.12171en_US
dc.identifier.issn1751-2972
dc.identifier.issn1751-2980
dc.identifier.urihttps://doi.org/10.1111/1751-2980.12171
dc.identifier.urihttps://hdl.handle.net/11436/3077
dc.descriptionWOS: 000341704400007en_US
dc.descriptionPubMed: 24980811en_US
dc.description.abstractObjectiveTo compare the patients' compliance with and the efficacy of existing treatments for Helicobacter pylori eradication, including moxifloxacin-based triple therapy, sequential treatment and the standard treatment. MethodsPatients with H.pylori infection were randomly assigned to three therapy groups. the triple therapy (MML) group was given moxifloxacin 400mg/day, metronidazole 500mg b.i.d. and lansoprazole 30mg b.i.d. for 10 days. the sequential treatment (AL-CML) group was administrated amoxicillin 1g b.i.d. and lansoprazole 30mg b.i.d. for the first 5 days, followed by clarithromycin 500mg b.i.d., metronidazole 500mg b.i.d. and lansoprazole 30mg b.i.d. for the second 5 days. the standard treatment (CAL) group received amoxicillin 1g b.i.d., clarithromycin 500mg b.i.d. and lansoprazole 30mg b.i.d. for 14 days. the eradication rates were evaluated by per-protocol (PP) analysis and intention-to-treat (ITT) analysis. ResultsThe eradication rates were 87.1, 85.9 and 85.2% by PP analysis and 87.1, 84.9 and 84.2% by ITT analysis in the MML, AL-CML and CAL group, respectively, and patients' compliance rates were 98.2, 96.5 and 97.1%, respectively. There were no significant differences in treatment efficacy and compliance rates in the MML, AL-CML and CAL groups (P>0.05). ConclusionsThe present study revealed that standard triple therapy, sequential therapy and moxifloxacin-based triple therapy are all effective treatment regimens in terms of H.pylori eradication rates and compliance with therapy in Turkey.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEradication rateen_US
dc.subjectHelicobacter pylorien_US
dc.subjectMoxifloxacinen_US
dc.subjectPatients' complianceen_US
dc.subjectResistanceen_US
dc.titleComparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication ratesen_US
dc.typearticleen_US
dc.contributor.departmentRTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.contributor.institutionauthorRakıcı, Halil
dc.contributor.institutionauthorAkdoğan, Remzi Adnan
dc.contributor.institutionauthorBedir, Recep
dc.contributor.institutionauthorÇiçek, Ayşegül Çopur
dc.contributor.institutionauthorYılmaz, Arif
dc.identifier.doi10.1111/1751-2980.12171
dc.identifier.volume15en_US
dc.identifier.issue9en_US
dc.identifier.startpage508en_US
dc.identifier.endpage513en_US
dc.relation.journalJournal of Digestive Diseasesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster